Breaking News, Trials & Filings

UCB’s Cimzia Gains Approval for RA

Enzon Pharmaceuticals, Inc. received approval from the FDA for Cimzia for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

Enzon Pharmaceuticals, Inc. received approval from the FDA for Cimzia for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products that use Enzon’s PEGylation technology.

“Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases,” said Jeffrey H. Buchalter, Enzon’s chairman and chief executive officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters